ATC Group: A10BJ01 Exenatide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10BJ01 in the ATC hierarchy

Level	Code	Title
`1`	A	Alimentary tract and metabolism
`2`	A10	Drugs used in diabetes
`3`	A10B	Blood glucose lowering drugs, excl. insulins
`4`	A10BJ	Glucagon-like peptide-1 (GLP-1) analogues
`5`	A10BJ01	Exenatide

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
PAREN	Parenteral	15 ug
PAREN	Parenteral	286 mg	(depot)

Active ingredients in A10BJ01

Active Ingredient
Exenatide
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that exhibits several antihyperglycaemic actions of glucagon-like peptide-1 (GLP-1). The amino acid sequence of exenatide partially overlaps that of human GLP-1. Exenatide has been shown to bind to and activate the known human GLP-1 receptor in vitro, its mechanism of action mediated by cyclic AMP and/or other intracellular signalling pathways. Exenatide increases, on a glucose-dependent basis, the secretion of insulin from pancreatic beta cells.